Fusion Antibodies Plc (GB:FAB)
LSE:FAB
Want to see GB:FAB full AI Analyst Report?
FAB Stock Chart & Stats
14.50 p
0.15 p(1.82%)
At close: 4:00 PM EST
14.50 p
0.15 p(1.82%)
Day’s Range― - ―
52-Week Range5.60 p - 21.00 p
Previous CloseN/A
Volume21.95K
Average Volume (3M)1.16M
Market Cap
£17.19M
Enterprise Value18.55M
Total Cash (Recent Filing)£252.00K
Total Debt (Recent Filing)£671.00K
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,021,880
10 Day Avg. Volume2,164,859
30 Day Avg. Volume1,162,225
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.81
Price to Sales (P/S)3.00
P/FCF Ratio-4.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Antibody CRO Business ModelSpecialized CRO focus on antibody discovery and engineering creates a durable, fee-for-service revenue model tied to long-term biotech/pharma outsourcing trends. Core capabilities support repeat project work and collaborations, making revenues more predictable across development cycles.
Low Financial LeverageMinimal leverage and a ~50% equity ratio give the company financial flexibility to endure operational losses and invest in R&D or customer projects without heavy interest burden. Low debt reduces bankruptcy risk and preserves optionality for strategic choices over months.
Improving Gross Margin And Recent Revenue GrowthA recent uptick in revenue and a materially improved gross margin indicate operational improvements in service delivery or pricing. If sustained, these trends support margin expansion potential and a path to narrowing operating losses as scale or utilization increases.
Bears Say
Deep Losses And Very Negative ROEExtremely large net losses and a deeply negative ROE reflect persistent unprofitability that can erode shareholder equity and limit reinvestment. Over months, continued heavy losses constrain strategic choices and increase reliance on external capital or dilution to sustain operations.
Weak Operating Cash GenerationNegative operating cash flow shows the business is not converting revenues into sustaining cash, forcing dependence on financing. Even with some FCF growth, a negative operating CF to income ratio signals cash burn that threatens runway and investment capacity absent new funding.
Small Scale And Limited ResourcesA very small headcount constrains capacity to scale projects, invest in new capabilities, or compete for large integrated contracts. Limited bench strength raises execution risk, makes revenue lumpy, and increases vulnerability if a few key clients or staff are lost.
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 5.60 p and its highest was 21.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £17.19M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Sep 03, 2026 which is in 137 days.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Nov 24, 2025. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,021,880 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.083%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Scancell Holdings
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---